MX389742B - Composiciones y metodos para reducir eventos adversos cardiovasculares graves. - Google Patents

Composiciones y metodos para reducir eventos adversos cardiovasculares graves.

Info

Publication number
MX389742B
MX389742B MX2016007231A MX2016007231A MX389742B MX 389742 B MX389742 B MX 389742B MX 2016007231 A MX2016007231 A MX 2016007231A MX 2016007231 A MX2016007231 A MX 2016007231A MX 389742 B MX389742 B MX 389742B
Authority
MX
Mexico
Prior art keywords
adverse cardiovascular
compositions
methods
mace
cardiovascular events
Prior art date
Application number
MX2016007231A
Other languages
English (en)
Spanish (es)
Other versions
MX2016007231A (es
Inventor
Kristin Taylor
Preston Klassen
Original Assignee
Nalpropion Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52575014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX389742(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nalpropion Pharmaceuticals Llc filed Critical Nalpropion Pharmaceuticals Llc
Publication of MX2016007231A publication Critical patent/MX2016007231A/es
Publication of MX389742B publication Critical patent/MX389742B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2016007231A 2013-12-06 2014-12-04 Composiciones y metodos para reducir eventos adversos cardiovasculares graves. MX389742B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361913216P 2013-12-06 2013-12-06
US201361914938P 2013-12-11 2013-12-11
US201461984580P 2014-04-25 2014-04-25
US14/322,810 US8969371B1 (en) 2013-12-06 2014-07-02 Compositions and methods for weight loss in at risk patient populations
PCT/US2014/068527 WO2015085044A1 (en) 2013-12-06 2014-12-04 Compositions and methods for reducing major adverse cardiovascular events

Publications (2)

Publication Number Publication Date
MX2016007231A MX2016007231A (es) 2016-08-04
MX389742B true MX389742B (es) 2025-03-20

Family

ID=52575014

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016007231A MX389742B (es) 2013-12-06 2014-12-04 Composiciones y metodos para reducir eventos adversos cardiovasculares graves.
MX2022001251A MX2022001251A (es) 2013-12-06 2016-06-02 Composiciones y metodos para reducir eventos adversos cardiovasculares graves.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001251A MX2022001251A (es) 2013-12-06 2016-06-02 Composiciones y metodos para reducir eventos adversos cardiovasculares graves.

Country Status (33)

Country Link
US (9) US8969371B1 (enExample)
EP (2) EP3076971B1 (enExample)
JP (2) JP6665094B2 (enExample)
KR (3) KR20230152800A (enExample)
CN (3) CN105899210A (enExample)
AU (1) AU2014360492A1 (enExample)
BR (1) BR112016012755A2 (enExample)
CA (1) CA2932127C (enExample)
CL (1) CL2016001362A1 (enExample)
CR (1) CR20160313A (enExample)
CY (1) CY1125114T1 (enExample)
DK (1) DK3076971T3 (enExample)
EA (1) EA201690964A1 (enExample)
EC (1) ECSP16057765A (enExample)
ES (1) ES2903391T3 (enExample)
HR (1) HRP20220058T1 (enExample)
HU (1) HUE057551T2 (enExample)
IL (3) IL300870A (enExample)
JO (1) JOP20140344B1 (enExample)
LT (1) LT3076971T (enExample)
MX (2) MX389742B (enExample)
PE (1) PE20161034A1 (enExample)
PL (1) PL3076971T3 (enExample)
PT (1) PT3076971T (enExample)
RS (1) RS62846B1 (enExample)
RU (1) RU2711638C2 (enExample)
SG (1) SG10201808055QA (enExample)
SI (1) SI3076971T1 (enExample)
TN (1) TN2016000231A1 (enExample)
TW (1) TWI661826B (enExample)
UY (1) UY35864A (enExample)
WO (1) WO2015085044A1 (enExample)
ZA (1) ZA201603831B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CN101573103A (zh) 2006-11-09 2009-11-04 奥雷西根治疗公司 用于施用重量减轻药物的单位剂量包装和方法
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
KR20120124423A (ko) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
RS67076B1 (sr) * 2012-06-06 2025-08-29 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
CN109565697B (zh) * 2016-08-11 2021-08-13 华为技术有限公司 基于非授权频谱的无线通信方法，基站和终端设备
US20250332152A1 (en) * 2021-12-09 2025-10-30 Incarda Therapeutics, Inc. Inhaled therapy for cardiac arrhythmia
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
IL58649A (en) 1978-11-10 1982-04-30 Beecham Group Ltd Pharmaceutical dispensing container
JPS59500418A (ja) 1982-03-16 1984-03-15 ザ　ロツクフエラ−　ユニバ−シテイ 胃腸能動作用障害を回復する方法
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
EP0294028B1 (en) 1987-05-04 1993-09-01 Eli Lilly And Company Fluoxetine useful for the treatment of diabetes
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
ATE214276T1 (de) 1994-09-19 2002-03-15 Du Pont Pharm Co Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
CA2220768A1 (en) 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
DE69736928T2 (de) 1996-05-07 2007-06-28 Pliva Istrazivanje I Razvoj D.O.O. Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
SK284305B6 (sk) 1996-06-28 2005-01-03 Ortho-Mcneil Pharmaceutical, Inc. Liečivo na liečbu obezity
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
WO1999017803A1 (en) 1997-10-03 1999-04-15 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US6048322A (en) 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
WO2001019321A2 (en) 1999-09-15 2001-03-22 Elan Pharmaceuticals, Inc. Methods for treating neuropathic pain using hetreoarylmethanesulfonamides
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
US20030144271A1 (en) 2000-01-22 2003-07-31 Albert Shulman Methods for the treatment of substance abuse
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
SI1299104T1 (sl) 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
ATE396738T1 (de) 2000-09-18 2008-06-15 Sanos Bioscience As Verwendung von glp-2-peptiden
EP1392250A2 (en) 2001-06-08 2004-03-03 Endo Pharmaceuticals Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US7914818B2 (en) 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
CA2483464C (en) 2002-05-17 2011-12-20 Duke University Method for treating obesity
JP2005531557A (ja) 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 選択的オピエート受容体モジュレーターとして効果的な化合物の使用
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
EP1539145A2 (en) 2002-09-13 2005-06-15 Eisai Co., Ltd. Method of treating tremors
WO2004071423A2 (en) 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
EP1613324A2 (en) 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
CA2525366A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
ES2344350T3 (es) 2003-09-25 2010-08-25 Euro-Celtique S.A. Combinaciones farmaceuticas de hidrocodona y naltrexona.
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
KR20060128995A (ko) 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
CN1968692A (zh) 2004-05-03 2007-05-23 杜克大学 影响体重减轻的组合物
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
AU2005271574A1 (en) 2004-08-03 2006-02-16 Orexigen Therapeutics, Inc. Combination of bupropion and a second compound for affecting weight loss
WO2007047351A2 (en) 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
JP5180092B2 (ja) 2005-11-22 2013-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
EP1954316A1 (en) 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2007145863A2 (en) 2006-06-05 2007-12-21 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
ES2636657T3 (es) 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc Composición farmacéutica
CA2693992C (en) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
AR063959A1 (es) 2006-11-09 2009-03-04 Orexigen Therapeutics Inc Formulaciones farmaceuticas en capas
CN101573103A (zh) 2006-11-09 2009-11-04 奥雷西根治疗公司 用于施用重量减轻药物的单位剂量包装和方法
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
WO2009035473A2 (en) 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
KR20120124423A (ko) * 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
JP2014508717A (ja) 2010-12-03 2014-04-10 オレキシジェン・セラピューティクス・インコーポレーテッド むちゃ食いまたは強迫性摂食を減少させるための方法
RS67076B1 (sr) * 2012-06-06 2025-08-29 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Also Published As

Publication number Publication date
TW201607536A (zh) 2016-03-01
IL245919A0 (en) 2016-07-31
ES2903391T3 (es) 2022-04-01
PL3076971T3 (pl) 2022-04-04
EP3076971B1 (en) 2021-10-20
US20180243288A1 (en) 2018-08-30
US20250144089A1 (en) 2025-05-08
WO2015085044A1 (en) 2015-06-11
DK3076971T3 (da) 2022-01-24
PE20161034A1 (es) 2016-11-13
LT3076971T (lt) 2022-02-10
TN2016000231A1 (en) 2017-10-06
RS62846B1 (sr) 2022-02-28
US20190374535A1 (en) 2019-12-12
RU2711638C2 (ru) 2020-01-17
US20150182524A1 (en) 2015-07-02
US8969371B1 (en) 2015-03-03
JP2020037593A (ja) 2020-03-12
PT3076971T (pt) 2022-01-26
EP4005571A1 (en) 2022-06-01
KR20230152800A (ko) 2023-11-03
AU2014360492A1 (en) 2016-06-23
CY1125114T1 (el) 2023-06-09
EP3076971A1 (en) 2016-10-12
IL300870A (en) 2023-04-01
IL282117A (en) 2021-05-31
US11998542B2 (en) 2024-06-04
JP6665094B2 (ja) 2020-03-13
ECSP16057765A (es) 2017-02-24
US10828294B2 (en) 2020-11-10
US9801875B2 (en) 2017-10-31
MX2016007231A (es) 2016-08-04
CN114404419A (zh) 2022-04-29
JOP20140344B1 (ar) 2021-08-17
US10231964B2 (en) 2019-03-19
NZ720620A (en) 2022-03-25
TWI661826B (zh) 2019-06-11
KR20220165791A (ko) 2022-12-15
MX2022001251A (es) 2022-02-23
US10231962B2 (en) 2019-03-19
ZA201603831B (en) 2023-05-31
EA201690964A1 (ru) 2016-12-30
EP3076971A4 (en) 2017-06-28
US20190314363A1 (en) 2019-10-17
KR102472432B1 (ko) 2022-11-30
US20150366860A1 (en) 2015-12-24
US20210069181A1 (en) 2021-03-11
SI3076971T1 (sl) 2022-04-29
US10835527B2 (en) 2020-11-17
BR112016012755A2 (pt) 2017-08-08
KR20160095076A (ko) 2016-08-10
CA2932127A1 (en) 2015-06-11
HRP20220058T1 (hr) 2022-04-15
CN105899210A (zh) 2016-08-24
HUE057551T2 (hu) 2022-05-28
CN117159547A (zh) 2023-12-05
US9119850B2 (en) 2015-09-01
SG10201808055QA (en) 2018-10-30
JP2016539164A (ja) 2016-12-15
US20160310485A1 (en) 2016-10-27
CL2016001362A1 (es) 2017-01-06
JP7204634B2 (ja) 2023-01-16
UY35864A (es) 2015-07-31
CA2932127C (en) 2023-05-02
CR20160313A (es) 2018-01-26

Similar Documents

Publication Publication Date Title
MX389742B (es) Composiciones y metodos para reducir eventos adversos cardiovasculares graves.
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
PH12015502310B1 (en) Pharmaceutical composition, methods for treating and uses thereof
DOP2013000007A (es) Pirimidinadas y triazinas condensadas y su uso
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
HK1217650A1 (zh) 用於治疗剧痛的组合物及方法
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
UA115357C2 (uk) Похідні піридин-4-ілу
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
MX384303B (es) Composiciones y métodos para metabolismo muscular mejorado.
WO2014146111A3 (en) Analgesic compounds and methods of use
GB2527233A (en) Composition comprising hydrocortisone
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
HK1229713A1 (en) Compositions and methods for reducing major adverse cardiovascular events
IN2013MU03428A (enExample)
AR120476A2 (es) Método para tratar un sujeto que tiene un riesgo de sufrir un evento cardiovascular grave; método para prevenir o retrasar el inicio de dicho evento, método para tratar un sujeto por sobrepeso u obesidad y uso de naltrexona y bupropión para la preparación de un medicamento
HK1225230A1 (zh) 用於减少热潮红发生的方法
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
CL2015000072A1 (es) Compuestos derivados de azaindol, inhibidores pi3k; metodo de preparacion; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento de tratornos inmunologicos, cancer y enfermedades cardiovasculares.
IN2013MU01983A (enExample)
CR20140489A (es) Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t